Fate Therapeutics (FATE) Stock Overview
A clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
FATE Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Fate Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.10 |
| 52 Week High | US$3.21 |
| 52 Week Low | US$0.91 |
| Beta | 2.52 |
| 1 Month Change | 65.78% |
| 3 Month Change | 150.00% |
| 1 Year Change | 169.57% |
| 3 Year Change | -34.46% |
| 5 Year Change | -96.05% |
| Change since IPO | -53.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| FATE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.2% | -2.4% | 0.7% |
| 1Y | 169.6% | 35.9% | 20.6% |
Return vs Industry: FATE exceeded the US Biotechs industry which returned 36.1% over the past year.
Return vs Market: FATE exceeded the US Market which returned 19.5% over the past year.
Price Volatility
| FATE volatility | |
|---|---|
| FATE Average Weekly Movement | 18.2% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: FATE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FATE's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 161 | Bob Valamehr | www.fatetherapeutics.com |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors.
Fate Therapeutics, Inc. Fundamentals Summary
| FATE fundamental statistics | |
|---|---|
| Market cap | US$362.50m |
| Earnings (TTM) | -US$129.91m |
| Revenue (TTM) | US$6.32m |
Is FATE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FATE income statement (TTM) | |
|---|---|
| Revenue | US$6.32m |
| Cost of Revenue | US$87.47m |
| Gross Profit | -US$81.15m |
| Other Expenses | US$48.76m |
| Earnings | -US$129.91m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | -1,284.83% |
| Net Profit Margin | -2,056.79% |
| Debt/Equity Ratio | 0% |
How did FATE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 17:21 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fate Therapeutics, Inc. is covered by 25 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Tazeen Ahmad | BofA Global Research |
| Amanda Murphy | BTIG |